This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

This study has been completed.
Information provided by (Responsible Party):
Inovio Pharmaceuticals Identifier:
First received: August 5, 2010
Last updated: December 8, 2011
Last verified: December 2011
DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines. DNA vaccines appear to be well tolerated in humans. Therefore, the investigators have developed our DNA vaccine, VGX-3100, to include plasmids targeting E6 and E7 proteins of both HPV subtypes 16 and 18. The investigators have chosen to deliver our candidate vaccines via electroporation (EP) using the CELLECTRA constant current device to deliver a small electric charge following intramuscular (IM) injection, since animal studies have shown that this delivery method increases the immune response to our DNA vaccine leading to a decrease in the size of tumors caused by HPV 16 and 18. In study HPV-001, the vaccine was given to subjects with a history of CIN 2 and 3 who had been previously treated by surgery. This study is proposed to vaccinate the same subjects with a fourth dose of the VGX-3100 to determine the safety and immune response.

Condition Intervention Phase
Human Papillomavirus (HPV) Biological: VGX-3100 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Previously Immunized With VGX-3100

Resource links provided by NLM:

Further study details as provided by Inovio Pharmaceuticals:

Primary Outcome Measures:
  • Safety and tolerability of a fourth dose of VGX-3100 [ Time Frame: through Month 6 (end of study) ]
    Safety and tolerability of a fourth dose of VGX-3100, administered by IM injection with EP to adult females who have been previously immunized with three doses of VGX-3100

Secondary Outcome Measures:
  • Humoral and cellular immune responses to VGX-3100 [ Time Frame: through Month 6 (end of study) ]
    Humoral and cellular immune responses to VGX-3100 in blood samples obtained from study subjects after a fourth dose of VGX-3100 (6 mg) in adult female subjects who have been previously vaccinated with a three dose series of VGX-3100 containing 0.6, 2 or 6 mg of DNA/dose.

Enrollment: 14
Study Start Date: July 2010
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 6mg of DNA/dose
Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
Biological: VGX-3100
DNA plasmid delivered via IM injection + electroporation using CELLECTRA device


Ages Eligible for Study:   18 Years to 46 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent in accordance with institutional guidelines;
  2. Successful enrollment in and completion of all study procedures and follow-up in study HPV-001.
  3. Female 18-46 years of age;
  4. Post surgical (including LEEP and conization) or ablative treatment and a diagnosis of CIN 2 or 3, while under physician care as per ASCCP guidelines (Appendix C);
  5. Normal ECG and CPK, as judged by Grade 0-1 as per Toxicity Grading Scale for Healthy Adults (Appendix B) done up to 30 days prior to administration of study treatment;
  6. Body mass index (BMI) ≤30 kg/m2;
  7. Women of child-bearing potential (WOCBP) agree to remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc), or have a partner who is sterile (i.e., vasectomy) from enrollment to study discharge;
  8. Able and willing to comply with all study procedures.

Exclusion Criteria:

  1. Active infection with herpes simplex virus (HSV);
  2. Pregnant or breast feeding subjects;
  3. Any concurrent condition requiring the continued use of systemic or topical steroids (excluding inhaled and eye drop-containing corticosteroids) or the use of immunosuppressive agents. All other corticosteroids must be discontinued > 4 weeks prior to Day 1 of treatment;
  4. Administration of any blood product within 3 months of enrollment;
  5. Administration of any vaccine within 6 weeks of enrollment;
  6. Patient is currently participating or has participated in a study with an investigational compound or device other than VGX-3100 within 30 days of signing informed consent;
  7. Metal implants at the site of injection;
  8. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements;
  9. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness must not be enrolled into this study;
  10. Any other conditions judged by the investigator that would limit the evaluation of a subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01188850

United States, North Carolina
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States, 27103
United States, Pennsylvania
Laurel Highlands, OB/GYN, P.C.
Hopwood, Pennsylvania, United States, 15904
Puerto Rico
Clinical Research Puerto Rico
San Juan, Puerto Rico, 00909
Sponsors and Collaborators
Inovio Pharmaceuticals
Principal Investigator: Robert Parker, MD Lyndhurst Gynecologic Associates
Principal Investigator: John Sunyecz, MD Laurel Highlands, OB/GYN, P.C.
Principal Investigator: Javier Morales, MD Clinical Research Puerto Rico
  More Information

Responsible Party: Inovio Pharmaceuticals Identifier: NCT01188850     History of Changes
Other Study ID Numbers: HPV-002
Study First Received: August 5, 2010
Last Updated: December 8, 2011

Keywords provided by Inovio Pharmaceuticals:
CIN 2 or 3
cervical cancer
Human Papillomavirus (HPV) processed this record on August 21, 2017